Pronunciation: kore-ee-ON-ik goe-NAD-oh-troe-pin
Class: Gonadotropin, Ovulation stimulant
- Injection, powder for solution 10,000 units
- Injection, powder for solution 10,000 units
Stimulates production of gonadal steroid hormones by stimulating interstitial cells (Leydig cells) of the testis to produce androgens and corpus luteum of the ovary to produce progesterone.
Bioavailability is 40% after subcutaneous administration; C max is reached in 6 h.
Distributed mainly to the gonads.
Metabolized mainly in the kidneys.
Blood concentrations decline in a biphasic manner with half-lives of approximately 6 to 11 h and 23 to 38 h, respectively. Within 24 h, 10% to 12% is excreted in the urine.
Special PopulationsRenal Function Impairment
No data available.Hepatic Function Impairment
No data available.
Indications and Usage
Prepubertal cryptorchidism not caused by anatomical obstruction; selected cases of hypogonadotropic hypogonadism (eg, hypogonadism secondary to pituitary deficiency) in men; induction of ovulation and pregnancy in anovulatory, infertile women in whom the cause of anovulation is secondary and not caused by primary ovarian failure and who have been appropriately pretreated with human menotropins.
Precocious puberty; prostatic carcinoma or other androgen-dependent neoplasm; prior allergic reaction to human chorionic gonadotropin (hCG); pregnancy.
Dosage and AdministrationPrepubertal Cryptorchidism
Children (4 y and older) Various authorities have advocated the following regimens Regimen 1
IM 4,000 units 3 times/wk for 3 wk.Regimen 2
IM 5,000 units every other day for 4 injections.Regimen 3
IM 15 injections of 500 to 1,000 units over a period of 6 wk.Regimen 4
IM 500 units 3 times/wk for 4 to 6 wk (if not successful, another course is begun 1 mo later using 1,000 units/injection).Hypogonadotropic Hypogonadism in Males
Adults and Children (4 y and older) Various authorities have advocated the following regimens Regimen 1
IM 500 to 1,000 units 3 times/wk for 3 wk, followed by same dose twice a week for 3 wk.Regimen 2
IM 4,000 units 3 times/wk for 6 to 9 mo, following which the dosage may be reduced to 2,000 units 3 times/wk for an additional 3 mo.Ovulation Induction in Females
IM 5,000 to 10,000 units 1 day after the last dose of menotropins. A dosage of 10,000 units is recommended in the labeling for menotropins.
- Follow manufacturer's instructions for reconstituting the powder for injection.
- Do not administer if particulate matter or discoloration is noted.
- Administer by IM injection.
Store vials between 59° and 86°F. Store reconstituted solution in the refrigerator (36° to 46°F) and use within 30 days ( Novarel and generic formulation) or 60 days ( Pregnyl ).
None well documented.
Laboratory Test Interactions
Interference with radioimmunoassay for gonadotropins, particularly luteinizing hormone.
Depression; fatigue; headache; irritability; restlessness.
Gynecomastia; ovarian hyperstimulation; precocious puberty; rupture of ovarian cysts resulting in hemoperitoneum.
Hypersensitivity reactions including angioedema, dyspnea, erythema, rash, shortness of breath, urticaria.
Arterial thromboembolism; ascites with or without pain; edema; multiple births; pain at injection site; pleural effusion.
Monitor women for signs of ovary overstimulation (eg, severe pelvic pain, abdominal pain or bloating). In adult men and women, the following hormone levels may be monitored depending on the nature of the diagnostic and therapeutic purpose: testosterone, dihydrotestosterone, 17-beta-estradiol, 17-beta-hydroxyprogesterone, progesterone, and androstenedione. In prepubertal males, testosterone and dihydrotestosterone may be followed.
Category X . May cause fetal harm.
Safety and efficacy in children younger than 4 y not established. The diluent for reconstitution may contain benzyl alcohol, which has been associated with a fatal gasping syndrome in premature infants.
Use with caution.
Special Risk Patients
Because chorionic gonadotropin may cause fluid retention, use with caution in patients with cardiac disease, epilepsy, migraine, or asthma.
Only health care providers experienced with fertility problems should use hCG in conjunction with human menopausal gonadotropins.
May induce precocious puberty in patients treated for cryptorchidism.
- Review the treatment regimen, including duration and monitoring, that will be required.
- If patient will be administering at home, teach patient how to store, prepare, and administer the dose, and dispose of used equipment and supplies.
- Warn women that close monitoring for overstimulation of the ovary is required and to report any of the following immediately to their health care provider: difficulty breathing, severe pelvic pain, nausea, vomiting, weight gain, stomach pain or bloating, diarrhea, or infrequent urination.
Copyright © 2009 Wolters Kluwer Health.
More about chorionic gonadotropin (hcg)
- Choriogonadotropin Alfa (AHFS Monograph)
- Gonadotropin, Chorionic (AHFS Monograph)
- Chorionic Gonadotropin (FDA)
- Choriogonadotropin Alfa (Wolters Kluwer)
- Chorionic Gonadotropin (Wolters Kluwer)